Hospitals, universities, and other institutions participating with MCL.
Name Description
Coordination and Data Management Group (CDMG) Provides logistic support, data management and protocol development for the biorepository, and conducts statistical and computational research for data analysis.
Johns Hopkins Molecular and Cellular Characterization Laboratory (Prostate) Together this work will yield highly relevant information that can be directly applied to the clinical management of localized prostate cancer. Specifically, it will yield an integrated signature that distinguishes localized - indolent tumors from localized tumors with lethal potential. Additionally we believe these signature will be critical in determining treatment strategies for individuals with prostate cancers of indeterminate kinetics.
JPL Informatics Center NASA/JPL Informatics Center
MD Anderson Cancer Center Molecular and Cellular Characterization Laboratory (Pancreatic) Dr. Maitra and team seek to develop a framework that integrates quantitative assessment of diagnostic imaging data with the host immune responses and systemic (circulating) biomarkers elicited by an underlying pancreatic cystic neoplasm, in order to generate algorithms that can reliably distinguish between indolent and aggressive lesions. Understanding the interactions between biology and physics of cystic lesions of the pancreas, where the genetic drivers of pancreatic cyst formation interact with the physical microenvironment to fuel malignant progression reflected in measurable imaging features and humoral immune responses, will offer transformative scientific and clinical approaches to pancreatic cancer and its early detection.
National Cancer Institute - Division of Cancer Biology
National Cancer Institute - Division of Cancer Prevention
Stanford Molecular and Cellular Characterization Laboratory (Prostate) A systematic study of the events in prostate cancer during its development and evolution will help address the issues of overtreatment by providing prognostic features and biomarkers that help select men for definitive treatment or observation.
UCLA-BU Molecular and Cellular Characterization Laboratory (Lung) Dr. Dubinett and team seek to understand the pathways underlying heterogeneity in screen-detected lung cancers through both integrated systems analysis of molecular, microenvironment and imaging characteristics of screen-detected lesions, and comparison of molecular and cellular characteristics between screen-detected and non-screen-detected tumors.
UCSF Molecular and Cellular Characterization Laboratory (Breast) Our goal is to identify better ways to screen for and treat the most aggressive cancers and avoid overdiagnosis and overtreatment as well as the inadvertent labeling of indolent lesions as cancers.
University of Vermont Molecular Characterization Laboratory (Breast) The Vermont Breast Cancer Molecular Characterization Laboratory will provide the consortium with scientific leadership, technical resources, and access to a large repository of retrospective and prospectively collected breast specimens linked to the rich data of the VBCSS.
Vanderbilt Molecular and Cellular Characterization Laboratory (Lung) We will be able to build integrated models of ADC behavior, validate a new genomic molecular test on circulating DNA and propose prospective studies that would eventually offer a different intervention based on these predictions i.e. surgery, vs no surgery, adjuvant immuno- or chemotherapy vs no adjuvant therapy and therefore reduce overtreatment and ultimately increase the rate of cure and reduce healthcare cost.